- Home
- AIRS vs ABEO Comparison
AIRS vs ABEO Comparison
Compare AIRS & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIRS | ABEO |
|---|---|---|
| Founded | 2012 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.3M | 281.0M |
| IPO Year | 2021 | 1980 |
Fundamental Metrics
Financial Performance| Metric | AIRS | ABEO |
|---|---|---|
| Price | $2.18 | $5.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $3.75 | ★ $18.20 |
| AVG Volume (30 Days) | 769.8K | ★ 1.4M |
| Earning Date | 11-07-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.29 |
| Revenue | ★ $157,554,000.00 | $400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.78 | $1,590.36 |
| P/E Ratio | ★ N/A | $3.97 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.53 | $3.93 |
| 52 Week High | $12.00 | $7.54 |
Technical Indicators
Market Signals| Indicator | AIRS | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 23.70 | 60.82 |
| Support Level | $2.11 | $4.80 |
| Resistance Level | $2.36 | $5.61 |
| Average True Range (ATR) | 0.28 | 0.27 |
| MACD | 0.10 | 0.03 |
| Stochastic Oscillator | 4.96 | 90.23 |
Price Performance
Historical ComparisonAbout AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.